NCT03110354View on ClinicalTrials.gov

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

March 9, 2021

Study Completion Date

March 9, 2021

Conditions
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Acute
Interventions
DRUG

DS-3201b

DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

27710

Duke University, Durham

37232

Vanderbilt University, Nashville

48109

University of Michigan, Ann Arbor

77030

MD Anderson Cancer Center, Houston

02115

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT03110354 - DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL) | Biotech Hunter | Biotech Hunter